In a presentation to investors, AstraZeneca laid out its game plan for building sales on existing therapies like Crestor while beefing up its pipeline of experimental drugs. But few analysts seemed to be won over by the presentation. AstraZeneca bought Cambridge Antibody Technology Group recently to help add to its portfolio of experimental therapies. And in an update of clinical trials, AstraZeneca said that the Phase III study of AZD6140, an oral antithrombotic, is in late-stage planning.
- here's the AP report [1] on AstraZeneca
Links:
[1] http://www.businessweek.com/ap/financialnews/D8I40K6G0.htm?sub=apn_home_down&chan=db